February

60-Day Notice: Contractor Drug Use Statement (February 7, 2020)

Noramco Inc. (February 3, 2020)

Spocannabis LLC (February 3, 2020)

IsoSciences, LLC (February 3, 2020)

Shelton W. Barnes, M.D.; Decision and Order (February 3, 2020)

Theresa L. Wendt, N.P.; Decision and Order (February 3, 2020)

Andrzej Kazimierz Zielke, M.D.; Decision and Order (February 3, 2020)

Kambiz Haghighi, M.D.; Decision and Order (February 3, 2020)

Solomon Adu-Beniako, M.D.; Decision and Order (February 3, 2020)

Stepan Company (February 3, 2020)

January 2020

Interim Final Rule: Placement of Lasmiditan in Schedule V (January 31, 2020)

Proposed Rule: Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl Into Schedule I (January 30, 2020)

Temporary Rule: Extension of Temporary Placement of cyclopentyl fentanyl, isobutyryl fentanyl, para-chloroisobutyryl fentanyl, para-methoxybutyryl fentanyl, and valeryl fentanyl in Schedule I (January 30, 2020)

Direct Final Rule: Additions to Listing of Exempt Chemical Mixtures (January 27, 2020)

Final Rule: Placement of 5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA in Schedule I (January 24, 2020)

Final Rule: Removal of 6β-Naltrexol From Control (January 24, 2020)

Final Rule: Placement of Brexanolone in Schedule IV (January 24, 2020)

S&B Pharma, Inc. (January 17, 2020)

Report of Theft or Loss of Controlled Substance; DEA Form 106 (January 15, 2020)

Final Rule: Placement of Solriamfetol in Schedule IV (January 7, 2020)

December 2019

Johnson Matthey Pharmaceutical Materials Inc. (December 27, 2019)

Janssen Pharmaceuticals Inc. (December 27, 2019)

Lisa Hamilton, N.P.; Decision and Order (December 27, 2019)

Siegfried USA, LLC (December 27, 2019)

Myoderm (December 27, 2019)

Stanley Brothers Bio Tec Inc. (December 26, 2019)

Kinetochem LLC (December 26, 2019)

Royal Emerald Pharmaceuticals Research and Development (December 26, 2019)

Agronomed Pharmaceuticals (December 26, 2019)

Final Rule; Technical Correction (December 16, 2019)

Jeffrey D. Olsen, M.D.; Decision and Order (PDF) (December 16, 2019)

Meridian Medical Technologies (December 16, 2019)

Novitium Pharma LLC (December 16, 2019)

Mylan Pharmaceuticals Inc. (December 16, 2019)

DEA Supports the Use of Medication Assisted Treatment for Use Disorder: Message for DATA Waived Practitioners And Those Eligible To Become DATA Waived (PDF) (December 12, 2019)

Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020 (December 2, 2019)

November

Patheon API Manufacturing, Inc. (November 22, 2019)

S&B Pharma, Inc. (November 22, 2019)

Chattem Chemicals (November 22, 2019)

Janssen Pharmaceuticals, Inc. (November 22, 2019)

Epic Pharma, LLC (November 22, 2019)

Fresenius Kabi USA, LLC (November 22, 2019)

GE Healthcare (November 22, 2019)

Mylan Technologies Inc. (November 22, 2019)

Rhodes Technologies (November 12, 2019)

Cambrex Charles City (November 12, 2019)

Cambridge Isotope Lab (November 12, 2019)

Placement of Solriamfetol in Schedule IV (Correction) (November 8, 2019)

Importer of Controlled Substances Registration (November 5, 2019)

Organix, Inc. (November 5, 2019)

Noramco Inc. (November 5, 2019)

Halo Pharmaceuticals, Inc. (November 5, 2019)

October

Proposed Rule: Placement of FUB-AMB in Schedule I (October 30, 2019)

Temporary Scheduling Order: Extension of Temporary Placement of FUB-AMB in Schedule I of the Controlled Substances Act (October 30, 2019)

Bulk Manufacturer of Controlled Substances Registration (October 28, 2019)

Euticals Inc. (October 28, 2019)

Lesly Pompy, M.D.; Decision and Order (October 28, 2019)

Catalent CTS, LLC (October 28, 2019)

Final Order: Placement of Cyclopropyl Fentanyl, Methoxyacetyl fentanyl, ortho-Fluorofentanyl, and para-Fluorobutyryl Fentanyl in Schedule I (October 25, 2019)

Suspicious Orders Report System (SORS) (October 23, 2019)

Management of Quotas for Controlled Substances and List I Chemicals (PDF) (October 23, 2019)

Johnson Matthey, Inc. (October 22, 2019)

ARCOS Retail Drug Summary Reporting Period - 2018

Bulk Manufacturers of Marihuana; Correction (October 11, 2019)

Cambridge Isotope Laboratories, Inc. (October 7, 2019)

Bulk Manufacturer of Controlled Substances Registration (October 1, 2019)

Importer of Controlled Substances Registration (October 1, 2019)

CreaGen Inc. (October 1, 2019)

Siemens Healthcare Diagnostics, Inc. (October 1, 2019)

Noramco Inc. (October 1, 2019)

September

Final Rule: New Single-Sheet Format for U.S. Official Order Form for Schedule I and II Controlled Substances (DEA Form 222) (September 30, 2019)

Importer of Controlled Substances Registration (September 20, 2019)

National Center for Natural Products Research NIDA MPROJECT (September 20, 2019)

Peter J. Waidzunas, D.D.S.; Decision and Order (September 20, 2019)

John Yolman Salinas, M.D.; Decision and Order (September 20, 2019)

Globyz Pharma, LLC (September 20, 2019)

Fisher Clinical Services, Inc. (September 20, 2019)

Fisher Clinical Services, Inc. (September 20, 2019)

Galephar Pharmaceutical Research Inc. (September 20, 2019)

Proposed Rule: Control of the Immediate Precursor Norfentanyl Used in the Illicit Manufacture of Fentanyl as a Schedule II Controlled Substance (September 17, 2019)

Proposed Rule: Designation of Benzylfentanyl and 4-Anilinopiperidine, Precursor Chemicals Used in the Illicit Manufacture of Fentanyl, as List I Chemicals (September 13, 2019)

Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020 (September 12, 2019)

Jeffrey Stein, M.D.; Decision and Order (September 6, 2019)